ClinicalTrials.gg
Active, not recruitingNCT06833008Updated Sep 30, 2026

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

A Phase 1/2 interventional study of IPN01195 in Advanced Solid Tumor, sponsored by Ipsen. Active, not recruiting at 13 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Sponsored by Ipsen · Phase 1/2, Interventional, and Treatment

Updated Sep 30, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new study drug IPN01195 in adults with advanced solid tumours.

The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body.

Read the detailed description

The study consists of two phases, called phase I and phase II.

Phase I will be conducted in two parts:

Part A: Phase I Part A study (dose escalation) is designed to find the dose range showing activity on the tumour that can be tolerated by the participants by testing different doses of IPN01195.

Part B: Phase I Part B of the study (dose confirmation) will assess the ability of study drug to prevent, slow down, or stop the growth of tumours (abnormal cell growths that can lead to cancer) and how the body processes and responds to the study drug when administered in a "low dose" or "high dose" and further explore the safety and tolerability.

These parts will consist of the following periods:

  • A period to assess eligibility (screening period).
  • A treatment period that will require at least two visits for the first month followed by one visit every month. There will be also one visit, at the end of treatment, at 30 days after the last administration of study drug.

An assessment visit will be required every 6 weeks up to Week 24 and every 12 weeks thereafter to measure the tumour again and to assess how it is evolving, whether it is getting bigger, smaller, is stable or has gone away.

Based on the results obtained from phase I, a phase II extension study will be included through to an updated study plan, to further evaluate the study drug.

In both study phases, participants will undergo blood samplings, urine collections, physical examinations and clinical evaluations. They may continue some other medications, but the details need to be recorded.

02

Conditions studied

  • Advanced Solid Tumor
03

In context

Lead sponsor

Ipsen is the lead sponsor of 289 studies on the registry; 17 are open to participants now.

Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥18 years of age or the country's legal age of majority if the legal age is more than 18 years at the time of signing the .
  • Participants with confirmed solid tumour for whom no suitable alternative standard therapy exists.
  • Participants must bear tumours harbouring selected classes of genetic alterations of MAPK pathway based on an analytically validated assay performed by an accredited laboratory.
  • Part A: Participants must consent to the use of or, if not available, collection of fresh tumour biopsy at screening, for central confirmation of mutation status.
  • Part B: Participants must consent to the use of archival tumour tissue or, if not available, collection of fresh tumour biopsy at screening, for MAPK genomic testing to confirm eligibility.
  • Participants must have per (RECIST) version 1.1
  • (ECOG)/performance status (PS) of 0 or 1
  • use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Gastrointestinal conditions that could impair absorption of IPN01195 (specific cases e.g. remote history of gastrointestinal surgery, may be enrolled after discussion with the medical monitor)
  • Any evidence of severe active infection or inflammatory condition.
  • Non-adequate cardiac function
  • Known psychiatric or substance abuse disorder, or any other cognitive disorder per the opinion of the investigator that would interfere with the participant's ability to cooperate with the requirements of the study.
  • Underlying medical conditions that, in the investigator's or sponsor's opinion, will obscure the interpretation of toxicity determination or AEs.
  • Known second either progressing or requiring active treatment within the last 2 years prior to first dose of the study intervention.
  • Active or
  • Current enrolment or past participation in any other clinical studies involving an study treatment within the last 28 days
  • (s) within 28 days prior to first dose of the study intervention or plan to receive such vaccines during the study.
  • Concurrent treatment with any other anti-cancer therapy (including radiotherapy or investigational agents).
  • of less than 28 days prior anti-cancer therapy (including chemotherapy, targeted agents, radiotherapy). If the participant was treated with an agent having a short half-life, washout can be \<28 days but not shorter than 5 times the half-life.
  • Condition requiring systemic treatment with either (>10 mg daily prednisone equivalents) or other medications within 2 weeks prior to first dose of the study intervention.
  • Non-adequate bone marrow function
  • Non-adequate renal function
  • Non-adequate hepatic function
  • Known (HIV) infection. HIV testing will be performed in any countries where mandatory per local requirements.
  • Known uncontrolled or untreated hepatitis infection.

    • (a) Known uncontrolled virus (HBV) infection.
    • (b) Known untreated current virus (HCV) infection.
  • Sensitivity to IPN01195 or any of its components.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Part A (dose escalation)

    IPN01195 will be administered at assigned dose level.

    Drug: IPN01195

  • Experimental
    Part B - (randomisation)

    Participants will be randomised to one of the two doses of interest once the PADR is determined

    Drug: IPN01195

Interventions

  • DrugIPN01195

    IPN01195 will be administered at assigned dose level.

06

What researchers measure

Primary outcomes

  1. Part A: Percentage of participants with dose limiting toxicity (DLT)

    Time frame: Part A: within 28 days of first dose.

  2. Part A and B: Percentage of participants experiencing treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TE SAEs).

    An Adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAE is an AE for which the start date is on or after the date that the intervention began.

    Time frame: From the first IPN01195 administration to 30 days after last dose.

  3. Part A and B: Percentage of participants with dose interruptions and permanent treatment discontinuations

    Time frame: From the first study drug administration to 30 days after last dose.

  4. Part B: Objective response rate (ORR)

    Objective response rate is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator per RECIST version 1.1.

    Time frame: Part B: At end of study (up to approximately 3 years)

Secondary outcomes

  1. Part A: Time to maximum observed drug concentration (Tmax) after single and multiple doses of IPN01195

    Time frame: Cycle 1: at Day 1 and at Day 15.

  2. Part A: Maximum observed drug concentration (Cmax) after single and multiple doses of IPN01195

    Time frame: Cycle 1: at Day 1 and at Day 15.

  3. Part A: Area under the plasma concentration time curve (AUCtau) after single and multiple doses of IPN01195

    AUCtau is defined as the concentration of drug over one dosing interval.

    Time frame: Cycle 1: at Day 1 and at Day 15.

  4. Part A: Geometric mean ratio of Cmax of IPN01195 administered in fed state relative to fasted state.

    Time frame: Between Day -8 and Day -3 (fasted period) and between Day -10 and Day -7 (fed state period)

  5. Part A: Geometric mean ratio of AUClast of IPN01195 administered in fed state relative to fasted state

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Between Day -8 and Day -3 (fasted period) and between Day -10 and Day -7 (fed state period)

  6. Part A: Geometric mean ratio of AUCinf of IPN01195 administered in fed state relative to fasted state

    AUCinf is defined as the concentration of drug extrapolated to infinite time.

    Time frame: Between Day -8 and Day -3 (fasted period) and between Day -10 and Day -7 (fed state period)

  7. Part A: Prolongation of corrected QT interval (QTc)

    Prolongation of QTc defined as the upper limit of 90% confidence interval for change from baseline QTc evaluated over Cycle 1 at the highest clinically relevant exposure.

    Time frame: Within 28 days of first dose.

  8. Part A: Objective response rate (ORR)

    The ORR is defined as the percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR) as determined by investigator per RECIST version 1.1

    Time frame: Part A: From first study drug administration to end of study (up to approximately 3 years)

  9. Part B: Duration of response (DoR)

    DoR defined as the time from first documented evidence of CR or PR until progressive disease, as determined by investigator per RECIST version 1.1.

    Time frame: Every 3 months until end of study or death (up to approximately 3 years)

  10. Part B: Progression-free survival (PFS)

    PFS is defined as the time from the date of first IPN01195 administration to the date of the first documented disease progression, as determined by investigator per RECIST version 1.1.

    Time frame: From first study drug administration to end of study (up to approximately 3 years)

  11. Part B: PFS rate at 4 months

    PFS rate at 4 months defined as the proportion of participants who remain alive and progression-free at 4 months, as determined by investigator per RECIST version 1.1.

    Time frame: At Month 4

  12. Part B: Disease control rate (DCR).

    DCR is defined as the percentage of participants with BOR of CR, PR or stable disease (SD), as determined by investigator per RECIST version 1.1

    Time frame: Part B:From first study drug administration to end of study (up to approximately 3 years)

07

Study locations

13 sites
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

Time frame: Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

Access criteria: Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

Data sharing details ↗ · www.ipsen.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2025 (actual). Primary completion is estimated for Apr 2028, 36 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Oct 2028 → Apr 2028 and completion Oct 2028 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2025
First posted
Feb 18, 2025
StartActual
Mar 14, 2025
Primary completionEst.
Apr 4, 2028was Oct 2028
CompletionEst.
Apr 4, 2028was Oct 2028
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Sep 30, 2026
Primary completion
Oct 3, 2028→Apr 4, 2028
Sep 30, 2026
Study completion
Oct 3, 2028→Apr 4, 2028
Sep 30, 2026
Enrollment
85 (estimated)→42 (actual)
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    Recruiting→Active, not recruiting
    Primary completion Oct 3, 2028→Apr 4, 2028
    Study completion Oct 3, 2028→Apr 4, 2028
    Enrollment 85 (estimated)→42 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06833008
Lead sponsor
Ipsen
Responsible party
Sponsor
First posted
Feb 18, 2025
Start date
Mar 14, 2025
Primary completion
Apr 4, 2028 (estimated)
Completion
Apr 4, 2028 (estimated)
Last update
Sep 30, 2026

Study contacts

Ipsen Medical Director
study director · Ipsen

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion